Summit Therapeutics (SMMT) Q4 2025 earnings summary

Executive summary

• Ivonescimab, a PD-1/VEGF bispecific antibody, leads an advanced clinical pipeline with multiple global Phase III trials in NSCLC, CRC, and head and neck cancer, supported by collaborations with GORTEC, GSK, and Revolution Medicines.

• FDA accepted the BLA for ivonescimab in EGFR-mutated NSCLC, with a PDUFA date set for November 14, 2026.

• Over 4,000 patients have been enrolled in clinical trials and more than 60,000 patients have received ivonescimab commercially in China.

• New Phase III ILLUMINE study in head and neck cancer will launch in collaboration with GORTEC, with enrollment to begin in early Q2 2026.

• The company is preparing for potential U.S. approval and commercial launch, with commercial readiness activities underway.

Financial highlights

• Ended 2025 with a cash position of $713.4 million and no debt.

• Q4 2025 GAAP operating expenses were $225 million, down from $234.2 million in Q3; annual GAAP operating expenses surged to $1,094.4 million in 2025, mainly due to $681.4 million in stock-based compensation.

• Non-GAAP operating expenses rose to $113.3 million in Q4 2025 from $103.4 million in Q3; annual non-GAAP operating expenses increased to $362.0 million in 2025.

• Q4 2025 GAAP net loss was $219.2 million, improved from $231.8 million in Q3; annual GAAP net loss widened to $1,079.6 million in 2025 due to stock-based compensation.

• Annual G&A spend (excluding stock-based compensation) was about $43 million, with a quarterly run rate of $10–11 million.

Outlook and guidance

• Interim PFS analysis for HARMONi-3 squamous cohort expected in Q2 2026; final PFS and interim OS data in H2 2026.

• HARMONi-3 non-squamous cohort enrollment to complete in H2 2026, with final PFS data anticipated in H1 2027.

• ILLUMINE Phase III study in head and neck cancer to begin enrollment in early Q2 2026.

• Additional global Phase III studies and novel combinations planned for 2026, with further details to be announced.

• Anticipates first U.S. approval for ivonescimab in Q4 2026, with commercial readiness activities underway.